Illumina Names Dr. Phil Febbo Chief Medical Officer
March 12 2018 - 4:05PM
Business Wire
Brings unmatched bench-to-bedside expertise to catalyze the
adoption of precision medicine
Illumina, Inc. (NASDAQ:ILMN) announced today the
appointment of Dr. Phil Febbo, a leading physician scientist, as
Chief Medical Officer (CMO), starting March 26, 2018. In his new
role, Dr. Febbo will be responsible for developing and executing on
the Company’s medical strategy to drive genomic testing into
healthcare practice.
This press release features multimedia. View
the full release here:
http://www.businesswire.com/news/home/20180312006000/en/
Illumina names Dr. Phil Febbo Chief
Medical Officer - Brings unmatched bench-to-bedside expertise to
catalyze the adoption of precision medicine. (Photo: Business
Wire)
“We are very excited to welcome Dr. Febbo, who comes to us at a
transformative time in the evolution of genomic medicine,” said
Garret Hampton, Ph.D., Executive Vice President of Clinical
Genomics at Illumina. “Phil brings a wealth of clinical and
scientific experience to Illumina, from understanding the genomic
basis of common human cancers, to the development of clinical tests
based on next generation sequencing. We believe that his experience
will ensure that Illumina is uniquely positioned to change medical
practice with the use of genomics.”
For the past 25 years, Dr. Febbo has worked at leading
institutions throughout the United States, most recently serving as
CMO of Genomic Health (NASDAQ:GHDX). Prior to joining Genomic
Health, Dr. Febbo served as Professor of Medicine and Urology at
the University of California, San Francisco (UCSF), where his
laboratory focused on using genomics to understand the biology and
clinical behavior of prostate cancer, and his clinical practice
focused on genitourinary oncology. While at UCSF, Dr. Febbo was the
co-leader of the Prostate Cancer Program at the Helen Diller Family
Comprehensive Cancer Center and the Program Principal Investigator
of the Translational Research Program for the Alliance for Clinical
Trials in Oncology.
Dr. Febbo holds a Bachelor of Arts degree in Biology from
Dartmouth College, received his M.D. degree at UCSF, and completed
his internal medicine residency at the Brigham and Women’s
Hospital. After his fellowship in medical oncology at the
Dana-Farber Cancer Institute, he was an Attending Physician in the
Genitourinary Oncology Center at Dana-Farber, Instructor at Harvard
Medical School, and a post-doctoral fellow in Dr. Todd Golub's
laboratory at Dana-Farber, as well as the Whitehead Institute
Center for Genomic Research of MIT (now the Broad Institute). In
2004, Dr. Febbo moved to Duke University Medical Center’s Institute
of Genome Sciences and Policy. He has been a member of the American
Society for Clinical Investigation since 2009.
About Illumina
Illumina is improving human health by unlocking the power
of the genome. Our focus on innovation has established us as the
global leader in DNA sequencing and array-based technologies,
serving customers in the research, clinical and applied
markets. Our products are used for applications in the life
sciences, oncology, reproductive health, agriculture and other
emerging segments. To learn more,
visit www.illumina.com and follow @illumina.
Use of forward-looking statements
This release contains forward-looking statements that involve
risks and uncertainties. These forward-looking statements are based
on our expectations as of the date of this release and may differ
materially from actual future events or results. Among the
important factors that could cause actual results to differ
materially from those in any forward-looking statements are (i) our
ability to further develop and commercialize our instruments and
consumables, and to deploy new products, services and applications,
and expand the markets for our technology platforms; (ii) our
ability to manufacture robust instrumentation and consumables;
(iii) our ability to successfully identify and integrate acquired
technologies, products or businesses; (iv) the future conduct and
growth of the business and the markets in which we operate; and (v)
challenges inherent in developing, manufacturing, and launching new
products and services, together with other factors detailed in our
filings with the Securities and Exchange Commission, including
our most recent filings on Forms 10-K and 10-Q, or in information
disclosed in public conference calls, the date and time of which
are released beforehand. We undertake no obligation, and do not
intend, to update these forward-looking statements, to review or
confirm analysts’ expectations, or to provide interim reports or
updates on the progress of the current quarter.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20180312006000/en/
Illumina, Inc.Investors:Jacquie Ross,
CFA858-882-2172IR@illumina.comorMedia:Lisa
Warshaw323-360-8778PR@illumina.com
Illumina (NASDAQ:ILMN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Illumina (NASDAQ:ILMN)
Historical Stock Chart
From Apr 2023 to Apr 2024